Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Smoldering Multiple Myeloma × citarinostat × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Smoldering Multiple Myeloma 1 Neoplasms, Plasma Cell 1

Interventions

daratumumab 2 Lenalidomide 2 poly ICLC 1 fludarabine phosphate 1 fludarabine 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 citarinostat 1 auricularum 1 PVX-410 vaccine 1 Diet, Mediterranean 1 Dexamethasone 1 Cyclophosphamide 1 Calcium Dobesilate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

Massachusetts General Hospital

Phase 1 Active not recruiting

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡